San Diego, CA, United States of America

Todd Macklin

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 25(Granted Patents)


Location History:

  • Bloomington, MN (US) (2015)
  • Brooklyn Park, MN (US) (2017 - 2019)
  • San Diego, CA (US) (2015 - 2020)
  • New York, NY (US) (2020)

Company Filing History:


Years Active: 2015-2020

where 'Filed Patents' based on already Granted Patents

16 patents (USPTO):

Title: The Innovations of Inventor Todd Macklin

Introduction

Todd Macklin is a notable inventor based in San Diego, CA, who has made substantial contributions to the field of pharmaceutical sciences. With 16 patents to his name, Macklin's work focuses on innovations that enhance our understanding and treatment of neurological conditions associated with GPR6.

Latest Patents

Macklin's latest inventions include two significant patents:

1. **Substituted pyrido[3,4-b]pyrazines as GPR6 modulators** - This invention provides compounds that are useful as modulators of GPR6, along with pharmaceutical compositions and methods for treating conditions associated with GPR6. The patent also details the processes for making these compounds and their intermediates.

2. **Tetrahydropyridopyrazines as modulators of GPR6** - Similar to the previous patent, this invention offers compounds of formula I which serve as GPR6 modulators, including pharmaceutical compositions and treatment methods for related conditions, as well as production processes for these compounds.

Career Highlights

Todd Macklin is currently associated with Takeda Pharmaceutical Company Limited, where he plays a pivotal role in advancing therapeutic strategies related to neurological disorders. His innovative approach to drug development has not only broadened the horizons of pharmacotherapy but also led to significant advancements in patient care.

Collaborations

Throughout his career, Macklin has collaborated with notable colleagues in the field, such as Holger Monenschein and Holly Reichard. These partnerships have fostered a dynamic environment for research and development, amplifying the impact of their collective work.

Conclusion

In summary, Todd Macklin stands out as a leading inventor whose patents and innovations in pharmaceutical compositions have the potential to change treatment paradigms for conditions related to GPR6. His dedication to research and collaboration continues to influence the pharmaceutical landscape significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…